Cerebral dopamine and GABA function in 22q11.2 deletion syndrome: PET and MRS study.
- Conditions
- Healthy volunteer, 22q11.2 deletion syndrome.
- Registration Number
- JPRN-UMIN000029593
- Lead Sponsor
- ational Institute of Radiological Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Not provided
I. Patients 1. Subjects with any organic brain disorder 2. Subjects with a severe physical complication 3. Subjects who has been taking any dopamine blocker. 4. Subjects who currently smokes 5. Subjects with metallic medical device in the body 6. Subjects with tattoo 7. Subjects with severe claustrophobia 8. Subjects who tends to suicide 9. Pregnant women 10. Subjects who was considered to be inappropriate to participate in the study II. Healthy volunteers 1. Subjects with any psychiatric disorder 2. Subjects with any organic brain disorder 3. Subjects with severe physical complication 4. Subjects who has been taking any dopamine blocker. 5. Subjects who currently smokes 6. Subjects with metallic medical device in the body 7. Subjects with tattoo 8. Subjects with severe claustrophobia 9. Pregnant women 10. Subjects who has participated in other study in recent 6 months. 11. Subjects who was considered to be inappropriate to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference of cerebral dopamine and GABA function between normal controls and patients with 22q11.2 deletion syndrome.
- Secondary Outcome Measures
Name Time Method Correlations between cerebral dopamine and GABA function and various clinical scales